PAG
RUBY

Private Advisor Group’s Rubius Therapeutics, Inc RUBY Stock Holding History

Private Advisor Group’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-700
Closed -$4K – 3704
2020
Q2 		$4K Buy
+700
New +$4.13K ﹤0.01% 3383

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Private Advisor Group's RUBY Position: Q3 2020 in Review

Private Advisor Group sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2020, closing a stake of 700 shares — an estimated $4K sold.

Private Advisor Group first reported a position in RUBY in Q2 2020 and held it in 1 quarter. The position peaked at $4K in Q2 2020. 84 funds tracked by Wall St. Rank hold RUBY as of Q3 2020.

  • Private Advisor Group reported no remaining Rubius Therapeutics, Inc position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 700 Rubius Therapeutics, Inc shares in Q3 2020, an estimated $4K.
  • Private Advisor Group first reported a position in Rubius Therapeutics, Inc in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Rubius Therapeutics, Inc position peaked at $4K in Q2 2020.
  • 84 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.